Health Reference LibraryInositol: what does it do, who does it help, and how do you take it?
This entry is part of the Nutri Tailor Health Reference Library — cited research on supplements, nutrients and adjacent areas of health.
Summary
Inositol is a sugar alcohol your body makes and food supplies, working inside cells as a messenger in insulin and mood-related signalling. The strongest supplement evidence sits in polycystic ovary syndrome, where a 2024 meta-analysis found myo-inositol improved menstrual regularity and insulin measures, and the 2023 international PCOS guideline includes inositol as an option while being clear that the evidence certainty is low. The studied dose is 2 to 4 g of myo-inositol a day, usually split into two doses, judged over three to six months for cycle effects. Its safety record is genuinely good, with digestive upset only at intakes far above the studied range. The myo form is the one to start with.
How it works
Inositol works as a second messenger inside cells, relaying hormone signals from the cell surface to the machinery that responds. Its best mapped role is in insulin signalling, where myo-inositol derivatives help pass the insulin message along, which is the mechanistic reason it was trialled in PCOS, a condition where insulin signalling runs poorly. It also participates in serotonin and other neurotransmitter pathways, which is why mood research took an early interest.
Effective dose
The PCOS trials mostly used 2 to 4 g of myo-inositol daily, commonly 2 g twice a day. Mood research used higher intakes, sometimes 12 g and above, where digestive tolerance becomes the limit. There is no established benefit from exceeding 4 g for metabolic purposes, and the studied pattern of twice daily with or without food is the one to copy.
Forms compared
Myo-inositol is the dominant form in the body and in the research, and it is the form to start with. D-chiro-inositol is a minor partner, and blends at a 40 to 1 myo to D-chiro ratio mirror the proportion found in blood. Powder is practical at gram doses and dissolves easily with a mildly sweet taste; capsules work but need several to reach studied intakes. The which form entry on this shelf covers the ratio question in full.
Timing
Split dosing, morning and evening, matches the trials and keeps blood levels steadier. Food makes no meaningful difference to absorption, so anchor the doses to routines you keep, such as breakfast and dinner. What matters is the months, not the minutes: cycle-level outcomes were measured at three to six months, not weeks.
Safety profile
A dedicated clinical safety review found inositol well tolerated, with side effects limited to mild digestive complaints, mainly at intakes of 12 g and above, far beyond the 2 to 4 g metabolic range. It is a substance the body makes and handles daily, which shows in the tolerability data. Pregnancy research on inositol exists and has not raised safety flags, but supplementation in pregnancy should still be a conversation with a midwife or GP.
Special populations
The evidence base is overwhelmingly women with PCOS, and that is where expectations should be calibrated highest. For anyone trying to conceive, the guideline position is fair: metabolic markers respond more reliably than pregnancy outcomes. Type 2 diabetes research exists but is thinner. In pregnancy, trials for gestational diabetes reported no safety signals, but this use belongs under professional guidance rather than self-direction.
Interactions
Inositol has no established interactions with common prescriptions. In PCOS it is often taken alongside metformin, and the trials did not flag problems with the combination, though anyone on diabetes prescriptions should involve their GP because improving insulin sensitivity can nudge blood sugar. It combines unremarkably with folic acid, which several trial protocols included.
Guideline positions
The anchors are the 2023 international evidence-based PCOS guideline, which includes inositol as an option while grading the evidence low certainty, the 2024 systematic review and meta-analysis reporting improved menstrual regularity and insulin measures on myo-inositol, a 2024 phase III randomised multicentre trial in the same territory, and the 2011 clinical safety review establishing tolerability up to high intakes.
Practical framework
Start with 2 g of [myo-inositol](/products/inositol) twice daily, run it for a full three months, and judge it against something concrete: cycle regularity across those months, or fasting glucose and related markers if you have blood results to compare. If nothing has shifted by six months, the evidence says a longer run is unlikely to change the answer. Powder into water or a morning drink is the cheapest way to hit the studied dose. For readers who decide on a supplement, Nutri Tailor stocks [Myo-Inositol 500mg Capsules](/products/inositol) in the UK.
Common misconceptions
Inositol is sometimes called vitamin B8, but it is not a vitamin at all, because the body makes it. It is not a fertility drug, and the fair reading of the 2023 guideline is that pregnancy outcomes remain unproven even where cycles and insulin markers improve. And more is not better: the metabolic evidence lives at 2 to 4 g, and doubling that adds digestive risk rather than effect.
Sources
- Carlomagno G, Unfer V 2011. Inositol safety: clinical evidences. European Review for Medical and Pharmacological Sciences 15(8):931-936, PMID 21845803.
- Teede HJ, Tay CT, Laven JJE, et al; International PCOS Network 2023. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. European Journal of Endocrinology 189(2):G43-G64, DOI 10.1093/ejendo/lvad096, PMID 37580861.
- Fitz V, Graca S, Mahalingaiah S, et al 2024. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. Journal of Clinical Endocrinology and Metabolism 109(6):1630, PMID 38163998.
- Multicentre phase III investigators (India), Eris Lifesciences sponsored 2024. A Phase III, Double-Blind, Randomized, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Metformin Hydrochloride and Myo-Inositol Compared to Metformin in Patients With Polycystic Ovary Syndrome. Cureus, December 2024, PMID 39803009.